Shandong Sinobioway Biomedicine Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jialin Yue

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	2.3yrs

Son yönetim güncellemeleri

Recent updates

There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump

Oct 08

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price

Aug 19

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues

Mar 06

CEO

Jialin Yue (56 yo)

2.3yrs

Görev süresi

CN¥766,500

Tazminat

Mr. Jialin Yue is GM & Director of Shandong Sinobioway Biomedicine Co., Ltd. since August 5, 2022 and August 22, 2022 respectively and was its Co-GM since April 10, 2022 until August 22, 2022.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jialin Yue	GM & Director	2.3yrs	CN¥766.50k	Veri yok
Wenjun Liu	Deputy GM & Non-Independent Director	2.3yrs	CN¥538.80k	Veri yok
Hui Zhao	Board Secretary & Employee Director	2.6yrs	CN¥792.90k	Veri yok
Ren Yanshen	Co-Founder	no data	Veri yok	Veri yok
Chen Zhangliang	Co-Founder	no data	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: 002581 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jialin Yue	GM & Director	2.3yrs	CN¥766.50k	Veri yok
Wenjun Liu	Deputy GM & Non-Independent Director	2.3yrs	CN¥538.80k	Veri yok
Hui Zhao	Board Secretary & Employee Director	2.3yrs	CN¥792.90k	Veri yok
Xiuyuan Yu	Vice Chairman	8.9yrs	CN¥995.40k	Veri yok
Xue Ming Yan	Member of the Supervisory Board	8.9yrs	Veri yok	Veri yok
Wenjie Yu	Director	2.3yrs	CN¥727.60k	Veri yok
Guiyuan Huang	Non-Independent Director	2.3yrs	CN¥212.50k	Veri yok
Zhe Zheng	Non-Independent Director	2.3yrs	CN¥33.30k	Veri yok
Yang Liu	Independent Director	2.3yrs	Veri yok	Veri yok
Jie Xiao	Independent Director	2.3yrs	CN¥33.30k	Veri yok
Yang Xia	Independent Director	2.3yrs	CN¥33.30k	Veri yok
Jianuo Zeng	Non-Employee Supervisor	2.3yrs	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002581 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Shandong Sinobioway Biomedicine Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, May 22, 2024

Shandong Sinobioway Biomedicine Co., Ltd. Announces Executive Appointments

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, Aug 22, 2022

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.067 (vs CN¥0.13 in 3Q 2023)

There's Reason For Concern Over Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Massive 43% Price Jump

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.003 loss per share (vs CN¥0.049 loss in 2Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) Business Is Yet to Catch Up With Its Share Price

Shandong Sinobioway Biomedicine Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

First quarter 2024 earnings released: CN¥0.042 loss per share (vs CN¥0.033 loss in 1Q 2023)

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, May 22, 2024

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 26% Price Boost Is Out Of Tune With Revenues

Shandong Sinobioway Biomedicine Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.061 in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.049 loss per share (vs CN¥0.033 profit in 2Q 2022)

Full year 2022 earnings released: CN¥0.022 loss per share (vs CN¥0.41 profit in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.061 (vs CN¥0.32 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.17 in 2Q 2021)

Shandong Sinobioway Biomedicine Co., Ltd. Announces Executive Appointments

Shandong Sinobioway Biomedicine Co., Ltd., Annual General Meeting, Aug 22, 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.037 in 1Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.021 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.045 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.29 loss per share (vs CN¥0.096 profit in FY 2019)

New 90-day low: CN¥9.90

New 90-day low: CN¥12.64

New 90-day low: CN¥15.21

New 90-day low: CN¥17.15

Third quarter earnings released

Shandong Sinobioway Biomedicine Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Beijing Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan

New 90-day low: CN¥17.55

First half earnings released

New 90-day low - CN¥19.50

Shandong Sinobioway Biomedicine Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş